- Home
- OPRX vs NTHI Comparison
OPRX vs NTHI Comparison
Compare OPRX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | NTHI |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 109.5M |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | OPRX | NTHI |
|---|---|---|
| Price | $8.06 | $4.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $16.67 | $15.00 |
| AVG Volume (30 Days) | ★ 238.0K | 217.1K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | $39,990.00 |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $8.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $3.01 |
| 52 Week High | $22.25 | $12.99 |
Technical Indicators
Market Signals| Indicator | OPRX | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 64.32 | 56.03 |
| Support Level | $7.80 | $4.18 |
| Resistance Level | $8.26 | $4.59 |
| Average True Range (ATR) | 0.58 | 0.64 |
| MACD | 0.09 | 0.18 |
| Stochastic Oscillator | 64.90 | 53.35 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.